Patents by Inventor Jukka T. Salonen
Jukka T. Salonen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120225047Abstract: The present invention discloses genes, SNP markers and haplotypes of susceptibility or predisposition to obesity, type 2 diabetes (T2D) and subdiagnosis of obesity and T2D and related medical conditions. Particularly, the present invention provides T2D and obesity associated markers from gene SUCLA2. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes and other related biomarkers are also disclosed. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of obesity and T2D.Type: ApplicationFiled: November 16, 2010Publication date: September 6, 2012Inventor: Jukka T. Salonen
-
Publication number: 20110111404Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.Type: ApplicationFiled: August 31, 2010Publication date: May 12, 2011Inventors: Jukka T. Salonen, Jelena Hyppönen, Jari Kaikkonen, Mia Pirskanen, Pekka Uimari, Juha-Matti Aaalto
-
Publication number: 20110111405Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.Type: ApplicationFiled: August 31, 2010Publication date: May 12, 2011Inventors: Jukka T. Salonen, Jelena Hyppönen, Jari Kaikkonen, Mia Pirskannen, Pekka Uimari, Juha-Matti Aalto
-
Patent number: 7901885Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.Type: GrantFiled: May 9, 2007Date of Patent: March 8, 2011Assignee: DSM IP Assets B.V.Inventors: Jukka T. Salonen, Jelena Hyppönen, Jari Kaikkonen, Mia Pirskanen, Pekka Uimari, Juha-Matti Aalto
-
Publication number: 20090155230Abstract: The present invention relates to previously unknown disease associations between various genes, loci and biomarkers and essential hypertension. The detection of these biomarkers provides novel in vitro methods and test kits which can be used as an aid when making risk assessment, molecular diagnosis or prognosis of HT or a HT related condition. The disclosed methods and test kits do not require interaction with the body of a subject during the biomarker detection. Instead the methods and test kits are for in vitro use (e.g. in a clinical laboratory) and typically biological samples for the biomarker analyses using a method or a test kit of this invention have been collected earlier in a different place. In addition the biomarkers provide methods and systems for identifying novel agents for preventing, treating and/or reducing risk of HT or a HT related condition. The HT associated genes can be used to develop novel therapies for prevention and/or treatment of essential hypertension.Type: ApplicationFiled: July 5, 2007Publication date: June 18, 2009Applicant: Oy Jurilab LtdInventors: Jukka T. Salonen, Juha-Matti Aalto, Pekka Uimari, Mia Pirskanen
-
Patent number: 7211387Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: GrantFiled: October 24, 2003Date of Patent: May 1, 2007Assignee: OY Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Patent number: 7029849Abstract: This invention relates to a method for detecting a risk of hypertension and for targeting antihypertensive treatment in a subject, the method comprising isolating genomic DNA from said subject, determining the DNA sequence comprising a nucleotide sequence encoding a variant ?2B-adrenoceptor protein.Type: GrantFiled: February 20, 2002Date of Patent: April 18, 2006Assignee: Oy Jurilab Ltd.Inventor: Jukka T. Salonen
-
Publication number: 20040214264Abstract: This invention relates to a nucleic acid encoding a variant human DDAH protein and to said variant DDAH protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant DDAH protein. Further this invention relates to a method for detecting or diagnosing a risk of, or predisposition to, cardiovascular disease and diabetes in a subject, for selecting treatment in a subject and for selecting subjects for studies testing cardiovascular and diabetes drugs, a method for the treatment of type 2 diabetes as well as to transgenic animals.Type: ApplicationFiled: April 19, 2002Publication date: October 28, 2004Inventors: Veli-Pekka Valkonen, Jukka T. Salonen, Mia Pirskanen, Tomi-Pekka Tuomainen, Juha Laakso, Reijo Laaksonen
-
Publication number: 20040152637Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. This invention also relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal. This invention further relates to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.Type: ApplicationFiled: March 26, 2004Publication date: August 5, 2004Applicant: Oy Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
-
Publication number: 20040142349Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes , dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: ApplicationFiled: October 24, 2003Publication date: July 22, 2004Applicant: Oy Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Patent number: 6740746Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: GrantFiled: March 20, 2001Date of Patent: May 25, 2004Assignee: Oy Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Patent number: 6696556Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.Type: GrantFiled: April 5, 2001Date of Patent: February 24, 2004Assignee: OY Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssönen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
-
Publication number: 20030003470Abstract: This invention relates to a method for detecting a risk of hypertension and for targeting antihypertensive treatment in a subject, the method comprising isolating genomic DNA from said subject, determining the DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein.Type: ApplicationFiled: February 20, 2002Publication date: January 2, 2003Inventor: Jukka T. Salonen
-
Publication number: 20030003453Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes , dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: ApplicationFiled: March 20, 2001Publication date: January 2, 2003Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Publication number: 20010016338Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to said variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant &agr;2B-adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor or said variant &agr;2B-adrenoceptor.Type: ApplicationFiled: April 5, 2001Publication date: August 23, 2001Applicant: OY Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen